BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Upfront License Payments Expensed to R&D by Year
Upfront License Payments Expensed to R&D ($M) ($M)
BeOne Medicines Upfront License Payments Expensed to R&D: $0.70M in FY2025, down 98.8% from a year earlier.
Latest, FY2025
0.70
Period ended Dec 31, 2025
Change on a year earlier
-98.8%
60 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Collaborative Arrangements Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Upfront License Payments Expensed to R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.70 | -98.8% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 60 | +28.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 46.8 | -31.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 68.7 | -17.7% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 83.5 | -23.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 110 | +119.0% | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 50 | – | Form 10-K (filed 2022-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Upfront License Payments Expensed to R&D ($M), annual FY2019–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-upfront
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.